Y-Mabs Therapeutics (YMAB) AI Stock Analysis

• Market Cap: $199.67M
• Dividend Yield: N/A
• Average Volume (3M): 279.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.81
• Revenue Growth: 3.38%
• EPS Growth: -36.40%
• Country: US
• Employees: 104
• Sector: Healthcare
• Sector Strength: 60
• Industry: Biotechnology
• EPS (TTM): -0.15
• Shares Outstanding: 45,276,917
• 10 Day Avg. Volume: 202,424
• 30 Day Avg. Volume: 279,514
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.43
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 3.93
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $16.45
• Price Target Upside: 287.06% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11

Y-Mabs Therapeutics faces significant challenges with profitability and cash flow despite revenue growth. The technical analysis indicates a bearish trend, and the valuation is not compelling due to negative earnings. While the earnings call presented some positive developments, the strategic realignment must address key challenges to improve the outlook.

Positive Factors

Financial Performance

YMAB reported a cash position that is expected to be sufficient to fund operations into 2027.

International Market Expansion

Danyelza continues to enter additional international markets, with a potential approval in a new ex-US market in 2025.

Potential Acquisition

The differentiated technology of the SADA platform is seen as being of interest to potential acquirers.

Negative Factors

Funding Concerns

YmAbs’ cash position could create a funding gap with key value inflection points unlikely to materialize in the near-term.

Potential Dilution

With a $67.2M cash position, Y-mAbs is likely to need additional dilutive capital.

Revenue Growth Challenges

The slowdown of growth for Danyelza has been a key focus, with reduction in US revenues due to unfavorable price mix not helping the narrative.

Y-Mabs Therapeutics Business Overview & Revenue Model

Company Description

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

How the Company Makes Money

Y-Mabs Therapeutics generates revenue primarily through the development and commercialization of its proprietary therapeutic products. The company earns money by bringing its drug candidates to market, which involves obtaining regulatory approvals, manufacturing the drugs, and distributing them through various healthcare channels. In addition to direct sales of their approved products, Y-Mabs may enter into strategic partnerships or licensing agreements with other pharmaceutical companies to co-develop or market its products, which can provide upfront payments, milestone payments, and royalties. Furthermore, the company may receive government grants or incentives for developing treatments for rare diseases, which can contribute to its revenue stream.

Y-Mabs Therapeutics Financial Statement Overview

Summary

Y-Mabs Therapeutics shows revenue growth and a strong equity position but struggles with profitability and cash flow sustainability. The biotech industry demands significant R&D investments, reflected in the financials. Although the balance sheet indicates stability, addressing operational losses is crucial for financial improvement.

Income Statement

Y-Mabs Therapeutics has shown revenue growth over recent years, with total revenue increasing from $20.75 million in 2020 to $87.68 million in 2024. However, the company is still facing significant challenges with profitability. The EBIT and EBITDA margins remain negative, indicating ongoing operational losses. The net profit margin is also negative, highlighting the unprofitable nature of the business at present.

Balance Sheet

The company maintains a strong equity position with a low debt-to-equity ratio of 0.009 in 2024, suggesting limited financial leverage risk. However, the return on equity remains negative due to net losses, and the equity ratio is robust, reflecting financial stability. The liquidity position, with substantial cash reserves, supports operational needs despite losses.

Cash Flow

Operating cash flow remains negative, indicating cash consumption from operations. Free cash flow has improved slightly but is still negative, showing reliance on financing activities. The operating cash flow to net income ratio suggests continued cash burn, posing challenges to sustainability without external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
87.69M	84.82M	65.27M	34.90M	20.75M
	Gross Profit
72.43M	73.40M	57.70M	32.38M	18.55M
	EBIT
-31.20M	-25.67M	-94.81M	-115.43M	-119.94M
	EBITDA
-31.20M	-24.94M	-94.73M	-54.49M	-119.54M
	Net Income Common Stockholders
-29.67M	-21.43M	-96.33M	-56.34M	-118.34M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
67.23M	78.64M	105.76M	181.56M	114.63M
	Total Assets
119.90M	127.87M	141.46M	212.78M	132.05M
	Total Debt
820.00K	1.42M	1.77M	3.63M	3.98M
	Net Debt
-66.41M	-77.22M	-104.00M	-177.93M	-110.66M
	Total Liabilities
27.90M	26.88M	32.23M	32.68M	26.21M
	Stockholders Equity
92.00M	100.98M	109.22M	180.11M	105.84M
Cash Flow		Free Cash Flow
-15.71M	-27.23M	-75.92M	-103.52M	-91.41M
	Operating Cash Flow
-15.71M	-27.23M	-75.92M	-102.56M	-91.23M
	Investing Cash Flow
0.00	0.00	0.00	61.04M	-2.79M
	Financing Cash Flow
4.31M	100.00K	84.00K	108.31M	2.00M

Y-Mabs Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YMAB, the sentiment is Negative. The current price of 4.25 is below the 20-day moving average (MA) of 4.42, below the 50-day MA of 4.75, and below the 200-day MA of 9.51, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 44.83 is Neutral, neither overbought nor oversold. The STOCH value of 49.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for YMAB.

Y-Mabs Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVRO	63 Neutral	$224.09M	―	-43.28%	―	-3.92%	-18.67%
OM	52 Neutral	$217.09M	―	-170.97%	―	-12.80%	28.80%
Sector *	52 Neutral	$5.35B	3.83	-41.61%	2.85%	17.10%	1.22%
ANIK	49 Neutral	$212.97M	―	-20.21%	―	-8.92%	31.98%
YMAB	44 Neutral	$199.67M	―	-30.74%	―	3.38%	-36.40%
CRDF	42 Neutral	$187.60M	―	-59.51%	―	40.16%	-2.76%
NGNE	34 Underperform	$242.03M	―	-30.28%	―	―	-140.77%

Y-Mabs Therapeutics Corporate Events

Y-mAbs Therapeutics Updates on Business and Clinical Trials

Y-mAbs Therapeutics, Inc. has released a corporate overview presentation on its investor relations website, which includes updates on its business operations, clinical trials, and development pipeline. This presentation is intended for investor meetings and a podium presentation at the J.P. Morgan Healthcare Conference, indicating the company’s ongoing engagement with investors and stakeholders in the biopharmaceutical industry.